Curient unveils Phase 1 data for 'mocaciclib' at ESMO: "Worked in terminal cancer patients who failed existing treatments"
Predicted impact: Medium
Phase 1 cancer data at ESMO; tiny revenue base, but a rights offering is pending, so data matters.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.